Article Text

PDF
Comparison of efficacy and adverse effect profile of high dose versus standard dose atorvastatin in acute ST elevation myocardial infarction patients
  1. Gailin B Sebastian1,
  2. T M Anoop2,
  3. Joby K Thomas1,
  4. Raju George1
  1. 1Department of Cardiology, Kottayam Medical College, Kottayam, Kerala, India
  2. 2Department of Medicine, Kottayam Medical College, Kottayam, Kerala, India
  1. Correspondence to T M Anoop, Department of Medicine, Kottayam Medical College, Kerala 686008, India; dranooptm{at}yahoo.co.in

Abstract

Objective To compare the efficacy and adverse effects of high and standard dose atorvastatin in ST elevation myocardial infarction (STEMI) patients.

Design A prospective, single-centre, randomised, double blind study.

Setting A tertiary care centre in Kerala, India, from January to June 2009.

Patients 121 consecutive acute STEMI patients eligible for thrombolytic therapy.

Interventions Pharmacological thrombolysis and atorvastatin therapy.

Main outcome measures Primary end points were mean change in low density lipoprotein and total cholesterol, serum glutamic pyruvic transaminase (SGPT), creatine phosphokinase (CPK) at 3 months of high dose (80 mg) and standard dose (20 mg) of atorvastatin.

Results There was no significant difference in the mean cholesterol levels at 3 months of therapy (mean reduction in total cholesterol and low density lipoprotein cholesterol were 48 mg%, 49 mg% in the 20 mg group compared with 54 mg% and 53 mg%, respectively, in the 80 mg group; p 0.39 and 0.4). There was a significant increase in SGPT at 1 week in the 80 mg group and atorvastatin was stopped in a significantly higher number of patients due to the increase in SGPT and CPK at 1 week in the high dose group (12% and 7% of patients; (p=0.04 and p=0.06, respectively).

Conclusion In acute STEMI patients treated with pharmacological thrombolysis, standard dose atorvastatin is equally effective as high dose atorvastatin in terms of reduction in cholesterol, with higher and earlier incidence of asymptomatic SGPT and CPK elevation in the high dose group.

  • Myocardial infarction
  • atorvastatin
  • acute myocardial infarction
View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the ethics committee, Kottayam Medical College.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.